PEMGARDATM shows continued effectiveness against dominant COVID variants

Invivyd, Inc. announced that its investigational monoclonal antibody PEMGARDATM (pemivibart) continues to neutralize dominant SARS-CoV-2 variants KP.3.1.1 and LB.1, with KP.3.1.1 representing 42.2% of circulating variants in late August. The company submitted data to the FDA for updates to the PEMGARDA Healthcare Providers Fact Sheet, highlighting its ongoing efficacy against evolving viral strains.